The rapidly emerging Buy Now Pay Later (BNPL) market is shaking the investment and spending world. What started off as a revolutionary payment solution is now gaining criticism as an unethical payment solution. Despite each person having ‘micro debt’, which might appear okay at a surface level, if its multiplied by millions of people …
Continue reading “How long will Afterpay and Zip Co be under the legal microscope?”
In my opinion, biotechnology is the most entertaining industry in the stock market. Why? Three reasons. 1) Biotech tends to be up even when the market is down. Because our ageing population continues to demand the best medicine to sustain a higher life expectancy. 2) Second, there is a range of top-quality biotechs under …
Continue reading “Will PAR’s H1 2020 financials trigger a surge this week?”
Before I start, I am obliged to remind our viewers that this is not advice only general commentary from my extensive research in this area. The cannabis industry evokes both unprecedented excitement and frustration in investors. Let me take you through the cannabis story. We first flashback to 2017 and 2018 where the industry was …
Continue reading “Will 2020 drive Cannabis growth or continue the bearish trend?”
When looking at the telecom industry we think of Telstra (ASX: TLS) and Optus. However, could the TPG-Vodafone merger put pressure on the telecom giants and change the industry? Time will tell. Today we will discuss the merger, whether the new ASX company is worth watching , and the impact on Telstra. TPG/Vodafone Merger …
Continue reading “How will the $15 Billion TPG-Vodafone merger impact Telstra ?”
JB HI-FI (ASX: JBH) is emerging as a popular, reliable and financially healthy stock in the recessionary retail market. JB HI-FI rocked investors with their recent financials. JB HI-FI is becoming not only a store where we buy our family presents but also an attractive investment. Today we will discuss why JB Hi-Fi’s rise on …
Continue reading “Why did JB HI-FI’S HY 2020 financials shock the market?”
Have you heard of Clinuvel Ltd (ASX: CUV)? The skin disorder company is famous in Germany and Australia. Clinuvel captivated investors in 2019 with an impressive 150% surge, leading to their high of $45 in October. However, CUV decreased 43% since its $45 high. Today we will discuss why Clinuvel’s plummet is an opportunity, what …
Continue reading “Does CUV’s 45% plummet provide a golden opportunity for investors?”
If you have 3 minutes, then read our uncomplicated, short and free crash course of the GFC. Every financial crisis teaches us invaluable lessons about the financial world, the stock market and how to make money. Here are 3 vital lessons that I learnt from the GFC that every young investor must understand. Lesson …
Commonwealth Serum Laboratories ASX: CSL, is one of the world’s most talked-about biotech companies. Therefore, it is no surprise that when CSL reached $321 (5/02/2020) the media attention surrounding the company exploded. Today we are discussing CSL’s financials, 2020 outlook and whether they are worth the investment in 2020. Financials Positives Investor excitement around CSL …
Continue reading “CSL up 928% in 10 years, will the exponential growth continue in 2020?”
Before I start, I am obliged to remind our viewers that this is not advice only general commentary from my extensive research in this area. Imugene Ltd (ASX:IMU) has one of the most exciting stock stories in the biotech industry. Why? Because IMU strives to cure cancer, through a range of new Immuno oncology therapies. …
Continue reading “Will IMU’s cancer trials cause a surge in stock price?”
Before I start, I am obliged to remind our viewers that this is not advice only general commentary from my extensive research in this area. The ASX 200 opened 1.5% lower this morning as investors reacted to global fears; as Chinese markets fell 9% at open and the Coronavirus continues to spread across China. The Australian …
Continue reading “5 hidden ASX companies surged today while the market was down”
Every cannabis stock has its story. Ecofibre (ASX: EOF) experienced an 88% YTD increase since listing at $1.70 back in March 2019. Unlike, your traditional cannabis company EOF operates under a unique business model. EOF’s cannabis footprint covers medicinal cannabis, plant-based protein and HEMP. EOF strives to use cannabis to change people’s lives. First, by …
Continue reading “Why this ASX cannabis stock is the only one worth watching in 2020?”
Before I start, I am obliged to remind our viewers that this is not advice only general commentary from my extensive research in this area. If you have not heard of Paradigm BioPharmaceuticals (ASX: PAR) then today is your lucky day. PAR is an Australian BioPharmaceutical company that aims to alleviate the cartilage degradation of …
Continue reading “Has the coronavirus created a possible entry for PAR ?”
Before I start, I am obliged to remind our viewers that this is not advice only general commentary from my extensive research in this area. After the dotcom crash in the 2000s, investors wanted to find a low-risk high return investment. Investors turned to the US housing market. Investors didn’t want to purchase your parent’s …
